We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test to Improve Diagnosis and Management of ALS

By LabMedica International staff writers
Posted on 27 Feb 2025

Amyotrophic lateral sclerosis (ALS) is often challenging to diagnose and predict in terms of disease progression. More...

An effective biomarker would be invaluable—not only in assisting with diagnosis but also in predicting prognosis, assessing disease stages, and monitoring patient progress or their response to treatment. Now, a new study has identified which blood tests are most effective for identifying and tracking ALS.

Researchers at Inserm Hospital (Paris, France) and University of Montpellier (Montpellier, France) conducted a study comparing three types of blood biomarkers: neurofilament light chain proteins, glial acidic proteins, and phosphorylated tau 181. Neurofilament light chain proteins are detectable in the blood when nerve cells are injured or die. Glial acidic proteins are released when the body attempts to repair such injuries, while phosphorylated tau 181 is linked to amyloid protein accumulation, a hallmark of Alzheimer’s disease. The study also assessed four different techniques to measure neurofilament light chain levels. The study, published in Neurology, involved 139 individuals diagnosed with ALS and 70 individuals with similar conditions such as lower motor neuron disease and primary lateral sclerosis. The participants’ blood was tested for these three biomarkers.

The study followed the ALS patients for an average of 3.5 years and the non-ALS group for approximately 12 years. During this period, 86% of the ALS patients passed away, compared to only 8% of those with other conditions. For neurofilament light chain proteins, those with ALS had levels three times higher in their blood compared to individuals with other diseases. The study found that tests measuring neurofilament light chain proteins accurately identified ALS patients over 80% of the time. In contrast, the accuracy of tests for glial acidic proteins and phosphorylated tau 181 was much lower, yielding correct results only about 50% of the time. Additionally, the researchers identified a specific threshold level of neurofilament light chain proteins that could predict survival in ALS patients. Within a year, over 40% of those with protein levels below the threshold were still alive, while none of those with higher protein levels survived.

“While more research needs to be done to confirm these findings, having better information about prognosis is valuable for people with ALS and their families as well as the doctors who treat them,” said study author Sylvain Lehmann, MD, PhD.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.